Deuk-Sil Oh
Research Subjects
Deuk-Sil Oh has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hyoun-Woo Kim
Postdoc Research Assistant, Jeollanam-Do Forest Resource Research Institute, Naju, Republic of Korea
2 shared publications - Seok-Myun Lee
Jeonnam Forest Resources Research Institute, Naju, Korea
2 shared publications - Bo-Hyun Yoon
Department of Psychiatry, Naju National Hospital, Naju, Korea
1 shared publication - Bo-Mi Jung
Jeonnam Forest Resources Research Institute, Naju, Korea
1 shared publication - Chan-Jin Oh
Jeollannam Do Forest Resources Res Off, Dept Forest Bio, Naju 58213, South Korea
1 shared publication - Da Hye Jeong
Master’s Student, Jeollanam-Do Forest Resource Research Institute, Naju, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 31 March 2023
- Published by Korean Society for Affective Disorders in Mood and Emotion
- Vol. 21 (1) , 1-7
The Effect of Forest Healing Program on the Psychological and Physiological Changes of the Employees: A Preliminary Study
Bo-Mi Jung, MS, Su-Mi Hyun, MA, Bo-Hyun Yoon, MD, PhD, Jye-Heon Song, MD, Kyung-Min Kim, MD, Hyoung-Yeon Kim, BS, Deuk-Sil Oh, MS, Seok-Myun Lee, MS. Mood Emot 2023;21:1-7. https://doi.org/10.35986/me.2023.21.1.1
- 31 March 2023
- Published by Korean Society for Affective Disorders in Mood and Emotion
- Vol. 21 (1) , 1-7
Open AccessThe Effect of Forest Healing Program on the Psychological and Physiological Changes of the Employees: A Preliminary Study
Bo-Mi Jung, MS, Su-Mi Hyun, MA, Bo-Hyun Yoon, MD, PhD, Jye-Heon Song, MD, Kyung-Min Kim, MD, Hyoung-Yeon Kim, BS, Deuk-Sil Oh, MS, Seok-Myun Lee, MS. Mood Emot 2023;21:1-7. https://doi.org/10.35986/me.2023.21.1.1
- Open Access
- 30 September 2022
- Published by The Oral Biology Research Institute at Chosum University in Oral Biology Research
- Vol. 46 (3) , 111-118
Evaluation of antioxidant and anticancer activities of fermented pericarp extract of Camellia japonica L. using Aspergillus oryzae in oral cancer
Eugene Cho, Hyoun Woo Kim, Da Hye Jeong, Seokmyon Lee, Deuk-Sil Oh, and Jin Kim. Oral Biol Res 2022;46:111-8. https://doi.org/10.21851/obr.46.03.202209.111
- 30 September 2022
- Published by The Oral Biology Research Institute at Chosum University in Oral Biology Research
- Vol. 46 (3) , 111-118
Open AccessEvaluation of antioxidant and anticancer activities of fermented pericarp extract of Camellia japonica L. using Aspergillus oryzae in oral cancer
Eugene Cho, Hyoun Woo Kim, Da Hye Jeong, Seokmyon Lee, Deuk-Sil Oh, and Jin Kim. Oral Biol Res 2022;46:111-8. https://doi.org/10.21851/obr.46.03.202209.111
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Acteoside Counteracts Interleukin‐1β‐Induced Catabolic Processes through the Modulation of Mitogen‐Activated Protein Kinases and the NFκB Cellular Signaling Pathway
Osteoarthritis (OA) is the most common degenerative joint disease with chronic joint pain caused by progressive degeneration of articular cartilage at synovial joints. Acteoside, a caffeoylphenylethanoid glycoside, has various biological activities such as antimicrobial, anti‐inflammatory, anticancer, antioxidative, cytoprotective, and neuroprotective effect. Further, oral administration of acteoside at high dosage does not cause genotoxicity. Therefore, the aim of present study is to verify the anticatabolic effects of acteoside against osteoarthritis and its anticatabolic signaling pathway. Acteoside did not decrease the viabilities of mouse fibroblast L929 cells used as normal cells and primary rat chondrocytes. Acteoside counteracted the IL‐1β‐induced proteoglycan loss in the chondrocytes and articular cartilage through suppressing the expression and activation of cartilage‐degrading enzyme such as matrix metalloproteinase‐ (MMP‐) 13, MMP‐1, and MMP‐3. Furthermore, acteoside suppressed the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase‐2, nitric oxide, and prostaglandin E2 in the primary rat chondrocytes treated with IL‐1β. Subsequently, the expression of proinflammatory cytokines was decreased by acteoside in the primary rat chondrocytes treated with IL‐1β. Moreover, acteoside suppressed not only the phosphorylation of mitogen‐activated protein kinases in primary rat chondrocytes treated with IL‐1β but also the translocation of NFκB from the cytosol to the nucleus through suppression of its phosphorylation. Oral administration of 5 and 10 mg/kg acteoside attenuated the progressive degeneration of articular cartilage in the osteoarthritic mouse model generated by destabilization of the medial meniscus. Our findings indicate that acteoside is a promising potential anticatabolic agent or supplement to attenuate or prevent progressive degeneration of articular cartilage.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessActeoside Counteracts Interleukin‐1β‐Induced Catabolic Processes through the Modulation of Mitogen‐Activated Protein Kinases and the NFκB Cellular Signaling Pathway
Osteoarthritis (OA) is the most common degenerative joint disease with chronic joint pain caused by progressive degeneration of articular cartilage at synovial joints. Acteoside, a caffeoylphenylethanoid glycoside, has various biological activities such as antimicrobial, anti‐inflammatory, anticancer, antioxidative, cytoprotective, and neuroprotective effect. Further, oral administration of acteoside at high dosage does not cause genotoxicity. Therefore, the aim of present study is to verify the anticatabolic effects of acteoside against osteoarthritis and its anticatabolic signaling pathway. Acteoside did not decrease the viabilities of mouse fibroblast L929 cells used as normal cells and primary rat chondrocytes. Acteoside counteracted the IL‐1β‐induced proteoglycan loss in the chondrocytes and articular cartilage through suppressing the expression and activation of cartilage‐degrading enzyme such as matrix metalloproteinase‐ (MMP‐) 13, MMP‐1, and MMP‐3. Furthermore, acteoside suppressed the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase‐2, nitric oxide, and prostaglandin E2 in the primary rat chondrocytes treated with IL‐1β. Subsequently, the expression of proinflammatory cytokines was decreased by acteoside in the primary rat chondrocytes treated with IL‐1β. Moreover, acteoside suppressed not only the phosphorylation of mitogen‐activated protein kinases in primary rat chondrocytes treated with IL‐1β but also the translocation of NFκB from the cytosol to the nucleus through suppression of its phosphorylation. Oral administration of 5 and 10 mg/kg acteoside attenuated the progressive degeneration of articular cartilage in the osteoarthritic mouse model generated by destabilization of the medial meniscus. Our findings indicate that acteoside is a promising potential anticatabolic agent or supplement to attenuate or prevent progressive degeneration of articular cartilage.